Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
AXNX

Axonics Modulation Technologies Inc

AXNX

57.88USD+0.53 (+0.92%)Market Closed
Watchlist

Market Summary

USD57.88+0.53
Market Closed
0.92%

AXNX Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

AXNX Stock Price

View Fullscreen

AXNX RSI Chart

AXNX Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-244.83

Price/Sales (Trailing)

8.56

EV/EBITDA

-1.5K

Price/Free Cashflow

-3.4K

AXNX Price/Sales (Trailing)

AXNX Profitability

EBT Margin

-10.73%

Return on Equity

-5.36%

Return on Assets

-4.96%

Free Cashflow Yield

-0.03%

AXNX Fundamentals

AXNX Revenue

Revenue (TTM)

342.6M

Revenue Y/Y

32.27%

Revenue Q/Q

0.22%

AXNX Earnings

Earnings (TTM)

-12.0M

Earnings Y/Y

124.17%

Earnings Q/Q

153.5%

Price Action

Last 7 days

3.4%

Last 30 days

8.3%

Last 90 days

-0.4%

Trailing 12 Months

-12.2%

How does AXNX drawdown profile look like?

AXNX Financial Health

Current Ratio

14.19

AXNX Investor Care

Shares Dilution (1Y)

7.33%

Diluted EPS (TTM)

-0.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023295.9M319.8M342.6M0
2022194.3M217.4M240.9M273.7M
2021119.6M150.3M161.9M180.3M
202039.0M52.8M86.7M111.5M
20192.0M3.3M4.4M13.8M
2018327.5K454.0K580.5K707.0K
2017000201.0K

Latest Insider Trading transactions for AXNX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 29, 2023
dearen danny l.
sold
-436,490
56.8717
-7,675
president & cfo
Sep 29, 2023
dearen danny l.
acquired
-
-
11,250
president & cfo
Aug 15, 2023
ford alfred j jr
sold
-920,671
62.3381
-14,769
chief commercial officer
Aug 08, 2023
carrel michael h
gifted
-
-
-500
-
Jul 28, 2023
ford alfred j jr
sold
-93,021
62.014
-1,500
chief commercial officer
Jun 26, 2023
mcnamara robert
acquired
-
-
3,000
-
Jun 26, 2023
lopez esteban
acquired
-
-
3,000
-
Jun 26, 2023
carrel michael h
acquired
-
-
3,000
-
Jun 26, 2023
snyderman nancy lynn md
acquired
-
-
3,000
-
Jun 26, 2023
kiernan jane e
acquired
-
-
3,000
-

1–10 of 50

Which funds bought or sold AXNX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
reduced
-97.52
-877,239
24,862
-%
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-35.02
-1,949,170
5,076,500
-%
Nov 22, 2023
Graham Capital Management, L.P.
sold off
-100
-2,652,750
-
-%
Nov 21, 2023
Walleye Capital LLC
reduced
-89.52
-1,602,940
211,404
-%
Nov 21, 2023
COMERICA BANK
reduced
-93.67
35,505
35,505
-%
Nov 17, 2023
Diversified Trust Co
added
15.02
152,312
698,245
0.03%
Nov 15, 2023
Bullseye Asset Management LLC
unchanged
-
234,000
2,325,000
1.30%
Nov 15, 2023
Integrated Wealth Concepts LLC
added
4.34
40,057
290,085
-%
Nov 15, 2023
iA Global Asset Management Inc.
reduced
-9.27
17,000
1,922,000
0.03%
Nov 15, 2023
MORGAN STANLEY
reduced
-39.9
-5,925,200
11,934,200
-%

1–10 of 47

Latest Funds Activity

Are funds buying AXNX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AXNX
No. of Funds

Schedule 13G FIlings of Axonics Modulation Technologies Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 10, 2023
vanguard group inc
10.28%
5,092,888
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.82%
4,863,283
SC 13G/A
Jan 31, 2023
blackrock inc.
7.3%
3,630,843
SC 13G/A
Jun 06, 2022
cooperatieve gilde healthcare iv u.a.
0%
0
SC 13G/A
Feb 14, 2022
credit suisse ag/
4.90%
2,273,198
SC 13G/A
Feb 09, 2022
vanguard group inc
6.27%
2,902,696
SC 13G
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 03, 2022
blackrock inc.
7.6%
3,525,549
SC 13G/A
Apr 08, 2021
alfred e. mann foundation for scientific research
4.0%
1,602,970
SC 13G/A

Recent SEC filings of Axonics Modulation Technologies Inc

View All Filings
Date Filed Form Type Document
Oct 31, 2023
10-Q
Quarterly Report
Oct 30, 2023
8-K
Current Report
Oct 06, 2023
3
Insider Trading
Oct 04, 2023
8-K
Current Report
Oct 03, 2023
4/A
Insider Trading
Oct 03, 2023
4
Insider Trading

Peers (Alternatives to Axonics Modulation Technologies Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.1B
40.0B
9.79% -0.70%
35.09
4.53
-11.26% -34.57%
71.3B
19.4B
-8.82% -4.53%
44.09
3.79
2.66% -16.58%
18.5B
15.0B
6.81% -29.70%
7.13
1.23
3.01% 209.09%
16.6B
3.8B
9.66% 15.63%
45.73
4.36
-1.48% -28.97%
MID-CAP
9.3B
12.7B
13.63% -12.11%
20.89
0.73
0.68% -30.25%
9.0B
2.7B
2.35% -23.26%
-56.61
3.32
-3.01% 97.36%
8.3B
3.4B
1.55% 18.98%
29.56
2.41
3.13% 18.17%
6.9B
3.9B
14.40% 9.17%
-31.57
1.75
-2.62% 73.28%
2.9B
342.6M
8.31% -12.22%
-244.83
8.56
42.19% 84.14%
2.5B
6.6B
-12.97% -7.64%
12.41
0.38
2.61% 0.62%
SMALL-CAP
1.1B
3.1B
3.77% -63.31%
-2.53
0.35
7.95% -550.16%
329.0M
163.3M
7.10% -27.48%
-13.39
2.01
7.14% -56.09%
282.7M
335.9M
6.52% -42.04%
43.86
0.84
4.71% 116.39%
72.1M
50.3M
-18.43% 13.66%
-4.75
1.43
3.23% 20.81%
5.2M
3.8M
8.25% -44.93%
-0.45
1.37
17.30% 10.67%

Axonics Modulation Technologies Inc News

Latest updates
Yahoo Finance06 Nov 202308:00 am32 days ago
Huron Daily Tribune30 Oct 202308:33 pm38 days ago
StreetInsider.com19 Aug 202007:00 am3 years ago
Yahoo Finance05 Aug 202007:00 am3 years ago
Yahoo Finance17 Jun 202007:00 am3 years ago
Nasdaq16 Jan 202008:00 am3 years ago
Yahoo Finance02 Nov 201907:00 am4 years ago
Business Wire02 Nov 201807:00 am5 years ago
MarketWatch31 Oct 201807:00 am5 years ago

Financials for Axonics Modulation Technologies Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue0.2%93,100,00092,894,00070,650,00085,918,00070,384,00068,980,00048,420,00053,135,00046,913,00045,869,00034,373,00034,783,00035,243,00015,213,00026,296,0009,950,5001,300,0001,488,0001,077,000494,000201,000
Gross Profit-1.5%69,104,00070,190,00052,500,00062,967,00051,260,00050,196,00033,242,00035,391,00031,194,00028,734,00020,399,00022,131,00021,809,0006,750,00016,401,0005,408,000677,000716,000529,000249,00095,000
Operating Expenses-15.2%69,791,00082,260,00066,866,00066,576,00067,635,00071,625,00056,775,00053,071,00047,696,00044,744,00042,015,00033,012,00030,578,00026,155,00031,106,00028,071,00025,724,00019,986,00014,148,0009,700,0007,637,000
  S&GA Expenses7.4%47,544,00044,270,00042,654,00043,824,00039,751,00039,381,00033,063,00031,338,00028,112,00025,411,00020,928,00018,284,00017,057,00014,220,00016,569,00016,301,00015,707,00010,750,0005,914,0001,416,000949,000
  R&D Expenses-8.7%8,167,0008,949,0008,056,0008,103,0007,936,0007,135,00011,236,00010,182,0008,648,0009,098,0009,369,0008,111,0007,719,0006,370,0006,855,0006,118,0004,855,0004,874,0004,219,0004,783,0003,898,000
EBITDA Margin100.0%--0.07-0.13-0.18-0.28-0.32-0.34-0.38-0.39-0.39-0.50-0.47-0.73-1.51-2.02-5.60-----
Interest Expenses-59.0%16,00039,000----1,000-1,0002,007,000170,000253,000256,000264,000329,000339,000367,000370,000360,000358,000188,000
Income Taxes-40.5%-427,000-304,000-807,000-522,000-520,000-465,000-1,111,000-2,487,000528,0003,296,000-555,000---1,000--1,000---
Earnings Before Taxes145.8%3,501,000-7,646,000-10,055,000143,000-16,772,000-21,908,000-23,779,000-17,653,000-16,722,000-21,852,000-23,058,000-11,348,000-9,168,000-19,783,000-14,615,000-22,751,000-25,006,000-19,060,000-13,117,000-9,665,000-7,566,000
EBT Margin100.0%--0.11-0.16-0.23-0.33-0.37-0.41-0.44-0.45-0.44-0.53-0.49-0.77-1.56-2.09-5.79-----
Net Income153.5%3,928,000-7,342,000-9,248,000683,500-16,252,000-21,443,000-22,668,000-15,166,500-17,250,000-25,148,000-22,503,000-11,348,000-9,168,000-19,783,000-14,616,000-22,751,000-25,006,000-19,061,000-13,117,000-9,665,000-7,566,000
Net Income Margin100.0%--0.10-0.16-0.22-0.31-0.35-0.41-0.44-0.47-0.45-0.53-0.49-0.77-1.56-2.09-5.79-----
Free Cashflow100.0%--19,465,000-1,575,0009,018,0002,884,000-1,476,000-9,458,000-7,860,000-3,678,000-12,323,000-25,706,000-29,337,000-19,794,000-13,528,000-24,021,000-28,513,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets1.8%66164966665963251452654856156644534234834921722012614615917242.00
  Current Assets4.4%47545547046544931330732133033222832833433620421211813815316535.00
    Cash Equivalents1.4%14714524023924120321322122923113124126928816017176.0083.0089.0098.0020.00
  Inventory6.9%75.0070.0066.0056.0058.0058.0062.0065.0070.0070.0071.0063.0044.0030.0019.0016.0013.008.005.004.002.00
  Net PPE3.3%7.006.007.007.007.007.007.007.006.006.006.006.006.006.005.003.003.003.003.003.003.00
  Goodwill-3.6%95.0099.0097.0094.0087.0095.0010310611010787.00----------
Liabilities3.4%50.0048.0089.0089.0083.0076.0062.0066.0071.0061.0011555.0054.0051.0045.0037.0034.0032.0028.0029.0018.00
  Current Liabilities10.9%36.0032.0066.0065.0061.0030.0026.0027.0028.0024.0024.0046.0039.0031.0020.0012.0016.0011.007.006.005.00
    LT Debt, Current---------0.000.000.0021.0015.0010.005.00-6.004.002.00--
    LT Debt, Non Current----------0.0075.00-6.0011.0016.0020.0014.0016.0018.0019.009.00
Shareholder's Equity1.7%61160157757055043846348249050433028729429817218392.00114131143-
  Retained Earnings1.0%-386-390-383-374-374-358-337-314-299-282-257-234-223-213-194-179-156-131-112-99.65-89.98
  Additional Paid-In Capital1.2%1,0221,0109829709618218128047967885905225185133673632502472452433.00
Shares Outstanding0.4%51.0050.0050.0050.0047.0045.0045.0046.0045.0043.0040.0040.0039.0036.0034.0034.0028.0028.0028.007.003.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations164.3%12,344-19,209-7819,3533,847-842-9,167-6,776-2,994-11,953-25,583-28,314-19,146-12,975-23,307-28,136-23,904-18,359-13,055-9,296-8,102
  Share Based Compensation2.4%11,47011,20410,7148,7578,2187,9057,1386,8446,6906,3275,3033,5823,7753,8163,9222,9212,7821,8751,142247101
Cashflow From Investing83.9%-11,053-68,623694-10,030-99,401-10,632-291-1,084-684-370-140,864-1,023-648-55311,87812,34217,45611,4404,049-48,1153,516
Cashflow From Financing113.0%878-6,7661,930161131,8834801,4442021,523112,57356,2151,0551,296141,495344110,49211130844.00135,5796.00

AXNX Income Statement

2023-09-30
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]    
Net revenue$ 93,100$ 70,384$ 256,644$ 187,784
Cost of goods sold23,99619,12464,85053,086
Gross profit69,10451,260191,794134,698
Operating expenses    
Research and development8,1677,93625,17226,307
General and administrative11,7789,38934,65929,974
Sales and marketing47,54439,751134,468112,195
Amortization of intangible assets2,3022,3176,8037,112
Acquisition-related costs08,2422,36820,447
Acquired in-process research & development0015,4470
Total operating expenses69,79167,635218,917196,035
Loss from operations(687)(16,375)(27,123)(61,337)
Other income (expense)    
Interest and other income4,2711,50112,1491,904
Interest and other expense(83)(1,898)774(3,026)
Other income (expense), net4,188(397)12,923(1,122)
Income (loss) before income tax benefit3,501(16,772)(14,200)(62,459)
Income tax benefit(427)(520)(1,538)(2,096)
Net income (loss)3,928(16,252)(12,662)(60,363)
Foreign currency translation adjustment(6,185)(12,057)636(29,625)
Comprehensive loss$ (2,257)$ (28,309)$ (12,026)$ (89,988)
Net income (loss) per share, basic (in USD per share)$ 0.08$ (0.34)$ (0.26)$ (1.31)
Weighted-average shares used to compute basic net income (loss) per share (in shares)49,244,98147,208,19248,973,25246,185,209
Net income (loss) per share, diluted (in USD per share)$ 0.08$ (0.34)$ (0.26)$ (1.31)
Weighted-average shares used to compute diluted net income (loss) per share (in shares)50,086,49147,208,19248,973,25246,185,209

AXNX Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 147,323$ 238,846
Short-term investments197,393118,365
Accounts receivable, net of allowance for credit losses of $380 and $321 at September 30, 2023 and December 31, 2022, respectively48,94444,817
Inventory, net74,90955,765
Prepaid expenses and other current assets6,8167,282
Total current assets475,385465,075
Property and equipment, net6,5566,798
Intangible assets, net80,27486,253
Other assets3,2456,813
Goodwill95,28794,414
Total assets660,747659,353
Current liabilities  
Accounts payable14,6669,070
Accrued liabilities5,9626,520
Accrued compensation and benefits12,99415,495
Operating lease liabilities, current portion1,9711,562
Other current liabilities032,600
Total current liabilities35,59365,247
Operating lease liabilities, net of current portion8767,555
Deferred tax liabilities, net13,65816,412
Total liabilities50,12789,214
Commitments and contingencies (Note 3)
Stockholders’ equity  
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2023 and December 31, 202200
Common stock, par value $0.0001, 75,000,000 shares authorized at September 30, 2023 and December 31, 2022; 50,669,203 and 49,546,727 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively55
Additional paid-in capital1,022,052969,545
Accumulated deficit(386,926)(374,264)
Accumulated other comprehensive loss(24,511)(25,147)
Total stockholders’ equity610,620570,139
Total liabilities and stockholders’ equity$ 660,747$ 659,353
AXNX
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
 CEO
 WEBSITEwww.axonics.com
 EMPLOYEES610

Axonics Modulation Technologies Inc Frequently Asked Questions


What is the ticker symbol for Axonics Modulation Technologies Inc? What does AXNX stand for in stocks?

AXNX is the stock ticker symbol of Axonics Modulation Technologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Axonics Modulation Technologies Inc (AXNX)?

As of Thu Dec 07 2023, market cap of Axonics Modulation Technologies Inc is 2.93 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXNX stock?

You can check AXNX's fair value in chart. The fair value of Axonics Modulation Technologies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Axonics Modulation Technologies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Axonics Modulation Technologies Inc a good stock to buy?

The fair value guage provides a quick view whether AXNX is over valued or under valued. Whether Axonics Modulation Technologies Inc is cheap or expensive depends on the assumptions which impact Axonics Modulation Technologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXNX.

What is Axonics Modulation Technologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 07 2023, AXNX's PE ratio (Price to Earnings) is -244.92 and Price to Sales (PS) ratio is 8.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXNX PE ratio will change depending on the future growth rate expectations of investors.